Scientific deep-dive

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

“These drugs make you lose muscle” is the most repeated criticism of GLP-1 medicines, and it is almost never accompanied by the comparison that would make it meaningful. A meta-analysis of 20 randomized trials in 15,782 people supplied it: on incretin drugs, lean mass makes up broadly the same fraction of the weight lost as it does on dieting.[1]

The comparison

Proportion of total weight lost that was lean mass. Pooled from 20 randomized trials.
InterventionLean share of weight lost
Semaglutide35.2% (95% CI 31.5–38.9)
Liraglutide26.8% (95% CI 23.1–30.5)
Tirzepatide25.4% (95% CI 22.8–28.0)
Lifestyle intervention26.2% (95% CI 24.1–28.3)
Lifestyle plus resistance training17.5% (95% CI 14.2–20.8)

The comparison between incretin drugs as a group and lifestyle intervention returned p=0.42, no significant difference.[1] Losing weight costs lean tissue. It costs about the same proportion whether the weight comes off through a drug or through dieting. The same arithmetic is behind the flatter buttocks people call “Ozempic butt”.

Incretin drugs against lifestyle intervention: no significant difference in how much of the lost weight was lean mass (p=0.42).

The row that actually helps

Adding resistance training brought the lean share down to 17.5%, the most favorable profile in the analysis.[1] It is the only option in the table that cuts the lean share well below dieting’s 26.2%.

That is the practical conclusion, and the exercise trial reached it from a different direction: there the drug alone did nothing for physical fitness, and training did. Two independent lines of evidence point to the same instruction, which is to lift something.

The authors’ own conclusion names three things: resistance training, adequate protein intake, and body composition monitoring built into weight-loss programs. None is exotic, and none is sold by anybody. Our protein calculator and strength cheat sheet cover the first two.

The difference between the drugs is not nothing

The class is not uniform, though. Semaglutide sits at 35.2% and tirzepatide at 25.4%, and those confidence intervals do not overlap.

This analysis cannot say what the gap means. It could reflect the drugs, the speed of loss they produce, the trial populations, or how body composition was measured in each study; heterogeneity across the pooled trials was moderate. The difference is real in the numbers but not yet explained, and it should not decide which one you pick.

What lean mass does and does not tell you

Every figure above is a scan measurement. Whether the person can do more or less is a different question, and one that scans answer badly. In one study muscle volume fell 9.3% while chair-rise and walking speed both edged better (see muscle volume versus muscle function).

So the full picture is three-part: lean mass falls with any weight loss, at a similar proportion drug or diet; resistance training substantially reduces that share; and the mass number alone does not establish that anyone has been harmed. Nor does it mean the drug slowed metabolism; the calorimetry studies are in does Ozempic slow your metabolism.

The pooled figure, across every drug class

A 2026 network meta-analysis pooled 41 randomized trials and 2,906 participants to place every major diabetes and obesity drug against a common reference on fat and lean mass at once.[2] Because every drug is set against the same reference, the numbers can be compared in a way that separate trials read side by side cannot.

Mean difference against placebo. Both columns are losses.[2]
DrugFat massLean body mass
Tirzepatide−10.70 kg (95% CI −13.42 to −7.99)−4.40 kg (−7.58 to −1.22)
LiraglutideModerate reduction−1.54 kg (−2.55 to −0.52)
SemaglutideModerate reductionNot among the significant reductions
SGLT2 inhibitorsModestMinor losses
Metformin, insulin, DPP-4 inhibitorsNeutral or gainNeutral

Do the arithmetic on the tirzepatide row: 4.40 kg of lean against 10.70 kg of fat means lean tissue made up roughly 29% of what was lost. That is the best pooled estimate available, and it sits close to what is generally expected of substantial weight loss by any means.

One node in that network is not a drug at all: liraglutide plus exercise. It came second for fat loss, behind only tirzepatide, and the reviewers report that exercise mitigated the lean mass loss liraglutide caused on its own. Of everything in this analysis, that is the finding someone can act on.

The network also shows the opposite effect. Insulin glargine was associated with fat mass gain, which is the mirror image of what these drugs do and a reminder that “a diabetes drug” is not one thing.

Frequently Asked Questions

No. Across 20 randomized trials in 15,782 people, lean mass made up 25% to 39% of the weight lost on incretin drugs and 26.2% on lifestyle intervention, with no significant difference between them (p=0.42). Lean loss is a property of losing weight rather than of the drugs.
Resistance training. Lifestyle intervention plus resistance training produced the most favorable profile in the analysis, with lean mass making up 17.5% of weight lost against roughly a quarter to a third for everything else.
In this analysis semaglutide's lean share was 35.2% and tirzepatide's 25.4%, and those confidence intervals do not overlap. What explains the difference is unclear. It could be the drugs, the rate of weight loss, the trial populations or how composition was measured. It is not currently a reason to choose between them.
The authors name adequate protein alongside resistance training and body composition monitoring, without a single number, because requirements scale with body size and activity. Our protein calculator works a target from established intake figures.
Not necessarily. These are scan measurements, and a separate study found muscle volume falling 9.3% while chair-rise time and walking speed both improved slightly. Mass is easy to measure; function is what matters.

References

  1. 1.Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41877354.
  2. 2.Rakhsha SS, Shahinfar H, Ebrahimi-Mousavi S, et al. Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42304171.

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.

6 min read

Ozempic Butt: What Large Weight Loss Changes in the Buttocks

No trial has measured buttock shape on semaglutide or tirzepatide. What changes is gluteal fat, some gluteal muscle and skin that does not retract, the same as with any large weight loss. What the DXA and MRI data show, what resistance training keeps, and what surgery can do.

11 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started

No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.

9 min read

How Far You Can Walk

Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

6 min read

Lifestyle Plus the Drug

Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

5 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

RxSpan MD

Knowing which pharmacy fills the vial: it names Belmar Pharmacy

9.1

Collective

From $59/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →